Cover Image
市場調查報告書

Convergence Pharmaceuticals Ltd.:產品平台分析

Convergence Pharmaceuticals Ltd. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 305681
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
Convergence Pharmaceuticals Ltd.:產品平台分析 Convergence Pharmaceuticals Ltd. - Product Pipeline Review - 2014
出版日期: 2014年05月30日 內容資訊: 英文 36 Pages
簡介

Convergence Pharmaceuticals Ltd.ha是著重於開發慢性疼痛用止痛藥的生物科技企業。

本報告提供Convergence Pharmaceuticals Ltd.的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Convergence Pharmaceuticals Ltd.的基本資料

Convergence Pharmaceuticals Ltd.概要

  • 主要資訊
  • 企業資料

Convergence Pharmaceuticals Ltd.:R&D概要

  • 主要的治療範圍

Convergence Pharmaceuticals Ltd.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Convergence Pharmaceuticals Ltd.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Convergence Pharmaceuticals Ltd.:藥物簡介

  • CNV-1014802
  • CNV-2197944
  • CNV-1061436
  • CNV-3000164
  • CNV-3000223 Small
  • Molecule to Inhibit ASK-1 for Chronic Pain Small
  • Molecule to Inhibit Cav2.2 Channel for Chronic Pain Small
  • Molecule To Inhibit GPR-84 For Chronic Pain Small
  • Molecule to Inhibit mPGES-1 for Chronic Pain Small
  • Molecule to Inhibit P2Y14 for Chronic Pain

Convergence Pharmaceuticals Ltd.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Convergence Pharmaceuticals Ltd.:最近的開發平台趨勢

Convergence Pharmaceuticals Ltd.:暫停中的計劃

Convergence Pharmaceuticals Ltd.:總公司和子公司的所地

附錄

目錄
Product Code: GMDHC04902CDB

Global Markets Direct's, 'Convergence Pharmaceuticals Ltd. - Product Pipeline Review - 2014', provides an overview of the Convergence Pharmaceuticals Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Convergence Pharmaceuticals Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Convergence Pharmaceuticals Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Convergence Pharmaceuticals Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Convergence Pharmaceuticals Ltd.'s pipeline products

Reasons to buy

  • Evaluate Convergence Pharmaceuticals Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Convergence Pharmaceuticals Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Convergence Pharmaceuticals Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Convergence Pharmaceuticals Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Convergence Pharmaceuticals Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Convergence Pharmaceuticals Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Convergence Pharmaceuticals Ltd. Snapshot
    • Convergence Pharmaceuticals Ltd. Overview
    • Key Information
    • Key Facts
  • Convergence Pharmaceuticals Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Convergence Pharmaceuticals Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Convergence Pharmaceuticals Ltd. - Pipeline Products Glance
    • Convergence Pharmaceuticals Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Convergence Pharmaceuticals Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Convergence Pharmaceuticals Ltd. - Drug Profiles
    • CNV-1014802
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CNV-2197944
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CNV-1061436
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CNV-3000164
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CNV-3000223
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit ASK-1 for Chronic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Cav2.2 Channel for Chronic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule To Inhibit GPR-84 For Chronic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit mPGES-1 for Chronic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit P2Y14 for Chronic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Convergence Pharmaceuticals Ltd. - Pipeline Analysis
    • Convergence Pharmaceuticals Ltd. - Pipeline Products by Target
    • Convergence Pharmaceuticals Ltd. - Pipeline Products by Route of Administration
    • Convergence Pharmaceuticals Ltd. - Pipeline Products by Molecule Type
    • Convergence Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action
  • Convergence Pharmaceuticals Ltd. - Recent Pipeline Updates
  • Convergence Pharmaceuticals Ltd. - Dormant Projects
  • Convergence Pharmaceuticals Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Convergence Pharmaceuticals Ltd., Key Information
  • Convergence Pharmaceuticals Ltd., Key Facts
  • Convergence Pharmaceuticals Ltd. - Pipeline by Indication, 2014
  • Convergence Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2014
  • Convergence Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2014
  • Convergence Pharmaceuticals Ltd. - Phase II, 2014
  • Convergence Pharmaceuticals Ltd. - Preclinical, 2014
  • Convergence Pharmaceuticals Ltd. - Pipeline by Target, 2014
  • Convergence Pharmaceuticals Ltd. - Pipeline by Route of Administration, 2014
  • Convergence Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2014
  • Convergence Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action, 2014
  • Convergence Pharmaceuticals Ltd. - Recent Pipeline Updates, 2014
  • Convergence Pharmaceuticals Ltd. - Dormant Developmental Projects,2014

List of Figures

  • Convergence Pharmaceuticals Ltd. - Pipeline by Top 10 Indication, 2014
  • Convergence Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2014
  • Convergence Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2014
  • Convergence Pharmaceuticals Ltd. - Pipeline by Top 10 Target, 2014
  • Convergence Pharmaceuticals Ltd. - Pipeline by Top 10 Route of Administration, 2014
  • Convergence Pharmaceuticals Ltd. - Pipeline by Top 10 Molecule Type, 2014
  • Convergence Pharmaceuticals Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top